Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation daily Stock Chart
Celgene Corporation
IndexS&P 500 P/E15.85 EPS (ttm)5.57 Insider Own0.34% Shs Outstand702.00M Perf Week0.74%
Market Cap61.94B Forward P/E8.51 EPS next Y10.37 Insider Trans-0.50% Shs Float696.89M Perf Month26.51%
Income4.16B PEG0.83 EPS next Q2.32 Inst Own76.20% Short Float2.21% Perf Quarter6.84%
Sales14.73B P/S4.21 EPS this Y109.10% Inst Trans-0.07% Short Ratio1.66 Perf Half Y3.52%
Book/sh6.92 P/B12.75 EPS next Y17.92% ROA8.70% Target Price102.78 Perf Year-16.76%
Cash/sh6.24 P/C14.15 EPS next 5Y19.08% ROE56.80% 52W Range58.59 - 107.29 Perf YTD37.67%
Dividend- P/FCF14.81 EPS past 5Y25.80% ROI20.00% 52W High-17.76% Beta1.57
Dividend %- Quick Ratio2.00 Sales past 5Y18.70% Gross Margin96.40% 52W Low50.59% ATR3.09
Employees7467 Current Ratio2.10 Sales Q/Q18.40% Oper. Margin31.10% RSI (14)75.78 Volatility1.33% 3.83%
OptionableYes Debt/Eq4.17 EPS Q/Q24.00% Profit Margin19.60% Rel Volume1.15 Prev Close87.01
ShortableYes LT Debt/Eq4.06 EarningsJan 31 BMO Payout0.00% Avg Volume9.32M Price88.23
Recom2.20 SMA2020.78% SMA5022.70% SMA2007.75% Volume10,729,415 Change1.40%
Jan-04-19Upgrade Robert W. Baird Neutral → Outperform
Jan-04-19Upgrade Goldman Sell → Neutral
Dec-21-18Resumed BTIG Research Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $100
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jan-26-18Reiterated SunTrust Buy $127 → $139
Jan-05-18Downgrade BofA/Merrill Buy → Neutral
Dec-27-17Downgrade Bernstein Outperform → Mkt Perform
Dec-22-17Reiterated Stifel Buy $149 → $130
Dec-08-17Upgrade Atlantic Equities Neutral → Overweight
Jan-15-19 04:19PM  Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter Investor's Business Daily
04:18PM  Here's How The Government Shutdown Will Affect These Medical Stocks Investor's Business Daily
03:02PM  David Rolfe Comments on Celgene
01:02PM  Takeda Pharmaceutical CEO Talks Big Pharma Trends
09:40AM  Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer Zacks
Jan-14-19 05:52PM  Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe Investor's Business Daily
05:45PM  Celgene (CELG) Stock Moves -0.45%: What You Should Know Zacks
04:08PM  U.S. lawmaker launches investigation into pharma drug pricing Reuters
04:00PM  David Rolfe's Wedgewood Partners 4th Quarter Client Letter
12:09PM  House Democrats launch drug-pricing probe into a dozen major health-care companies CNBC
08:45AM  Biotech is in the midst of major breakout, but one technician says buyer beware CNBC
Jan-13-19 07:55PM  INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Merger PR Newswire
Jan-12-19 06:00PM  3 Top Biotech Stocks to Buy in January Motley Fool
06:00AM  Morningstar Runs the Numbers Morningstar
Jan-11-19 08:00PM  Why Bristol-Myers Squibb Can Be a Sweet Pill for Investors
04:43PM  Here are the best Dow and S&P stocks so far in 2019 MarketWatch
03:06PM  7 Pharmaceutical Stocks That Just Raised Prices This Year InvestorPlace
10:31AM  Biotech stocks are off to the best start of the year since 2012 on heels of J.P. Morgan conference CNBC
09:59AM  The Loxo Oncology Purchase Eventually Could Help Eli Lilly Stock InvestorPlace
09:56AM  Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer Zacks
09:04AM  3 Biotech Stocks Bubbling Away Investopedia
06:22AM  4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019 Zacks
Jan-10-19 05:22PM  Ex-Juno executives reportedly seeking up to $1 billion for new Seattle startup American City Business Journals
04:13PM  Will Pfizer Join The Buying Spree With This Small Biotech Stock? Investor's Business Daily
03:23PM  3 Biggest Stories at the J.P. Morgan Healthcare Conference This Year Motley Fool
11:35AM  James Inhofe Sold Celgene, XPO, and Aptiv Stock
09:56AM  Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting Zacks
Jan-09-19 07:32PM  [$$] Big Pharmas Cancer Race The Wall Street Journal
07:21PM  [$$] Big Pharma's Cancer Race The Wall Street Journal
11:45AM  Deal Making in Biotech Heating Up ACCESSWIRE
09:33AM  Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus Zacks
08:51AM  The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo Zacks
06:36AM  3 Reasons Buying Celgene Right Now Makes Sense Motley Fool
04:06AM  Synergy Is a Myth: Cost-Cutting Breaks Mergers and Acquisitions
Jan-08-19 05:45PM  Celgene (CELG) Gains But Lags Market: What You Should Know Zacks
05:31PM  Celgene (CELG) Provides Guidance for 2019, Updates Pipeline Zacks
02:39PM  Here's Why Acceleron Pharma Fell 17.7% in December Motley Fool
02:11PM  Is It Time to Sell Celgene Stock After the Bristol-Myers Squibb Offer? InvestorPlace
11:15AM  CELGENE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG PR Newswire
09:58AM  Lilly Offers $8B to Acquire Cancer-Focused Small Biotech Loxo Zacks
09:52AM  Crowded Cancer Space Triggers Big M&A Deals: More in Store? Zacks
08:56AM  4 Biotechs That Are Potential Buyouts Post Celgene Deal Zacks
07:00AM  BMS/ Celgene Deal Could Spark M/A Activity ACCESSWIRE
06:01AM  Bull of the Day: Editas Medicine (EDIT) Zacks
04:29AM  How Takeda's $62 Billion Shire Deal Reshapes Pharma World Bloomberg
Jan-07-19 10:00PM  3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't Motley Fool
07:01PM  Jim Cramer: These Pharma Deals Are Game Changers
06:14PM  Epizyme to File NDA for Tazemetostat in Follicular Lymphoma Zacks
04:53PM  Biotech's big conference living up to reputation with big deals, big costs American City Business Journals
03:36PM  Soon-Shiongs NantCell gets $30 million from Celgene American City Business Journals
03:18PM  Celgene Expects to Generate Up to $17.2 Billion in Revenue in 2019
03:17PM  5 Must-See Stock Charts for Tuesday, Including Roku InvestorPlace
01:45PM  Celgene buyers going to do great, says Jim Cramer CNBC Videos
09:42AM  Bristol-Myers and Celgene CEOs talk acquisition deal CNBC Videos
08:29AM  The tech boom in corporate real estate Fox Business Videos
07:59AM  Celgene provides 2019 profit and sales outlooks above expectations MarketWatch
07:30AM  Celgene Corporation Announces 2019 Financial Guidance and Key Milestones Business Wire
07:02AM  5 Things to Watch for at the JPMorgan Healthcare Conference Investopedia
04:00AM  The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie Zacks
03:30AM  Tough Days for Giants Apple, Bristol-Myers Motley Fool
12:15AM  Should Investors Like Bristol-Myers' Buyout of Celgene? Motley Fool
Jan-06-19 06:15PM  Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene Motley Fool
11:00AM  2019 J.P. Morgan Healthcare Conference Roundup Motley Fool
10:00AM  All the Pre-JPM News Healthcare Investors Need to Know Motley Fool
09:16AM  The Week Ahead In Biotech: Conferences, Clinical Trials Benzinga
Jan-04-19 04:24PM  Bristol To Become Top 5 Pharma And Other Fallout From Celgene Takeover Investor's Business Daily +5.56%
04:06PM  Stock Market Rally Extends On Fed Chairman Powell, Jobs; Apple, Tesla, Delta Disappoint; Bristol-Myers Buys Celgene: Weekly Review Investor's Business Daily
01:46PM  CELGENE CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger Business Wire
01:31PM  Manufacturing, Apple, & Jobs: This Week's Top Market Stories Zacks
12:16PM  Here's Why bluebird bio Shares Got Knocked Down 19.3% in December Motley Fool
11:32AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Celgene Corporation to Bristol-Myers Squibb Company is Fair to Shareholders GlobeNewswire
11:30AM  Regeneron Stock Is the Latest Biotech Bottle Rocket
10:13AM  Bristol-Myers Becomes a Cancer-Fighting Giant With Celgene Buyout InvestorPlace
10:07AM  Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate Zacks
10:02AM  Trump's FDA may greenlight drug-prescribing apps: Report Fox Business Videos
10:01AM  Company News For Jan 4, 2019 Zacks
10:01AM  Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus Zacks
09:39AM  Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal Reuters
09:36AM  Bristol-Myers to Acquire Leading Biotech Celgene for $74B Zacks
09:26AM  Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal Reuters
08:07AM  Should Celgene Investors Take Bristol's Money and Run? Motley Fool
08:01AM  Heres What Bristol-Myers Squibb Will Look Like After Acquiring Celgene Motley Fool
07:00AM  Bristol Broadens Pipeline With Celgene Buy Morningstar
06:28AM  Biotech industry will continue to consolidate, sector ana... CNBC Videos
Jan-03-19 08:14PM  [$$] Advances in Cancer Drugs Fuel Blockbuster Deal The Wall Street Journal +20.69%
07:42PM  Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal Reuters
07:08PM  Cramer Remix: The monumental deal you might've missed CNBC Videos
06:59PM  Cramer Remix: The monumental deal you might've missed CNBC
06:01PM  Bristol-Myers Squibb buying Celgene in $74B deal Associated Press
05:56PM  Biotechs build buzz, rack up deals ahead of big JPM conference American City Business Journals
05:47PM  Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal Reuters
05:46PM  Factbox - Bristol-Myers' $74 billion Celgene buy has investors looking for next deal Reuters
05:46PM  Celgene Corporation -- Moody's reviews Celgene's Baa2 rating for upgrade Moody's
05:27PM  Bristol-Myers Loan for Celgene to Rank Among Top 10 Ever Bloomberg
05:27PM  Heres What Celgene Shareholders Are Getting From Bristol-Myers Squibb Motley Fool
05:26PM  Dow Tumbles 660 Points Because It Could Go Either Way
05:01PM  What Happened in the Stock Market Today Motley Fool
04:55PM  3 Things to Know at Market Close: Apple, Bristol-Myers and the Jobs Report
04:52PM  Father and son advised on opposite sides of Bristol-Celgene deal Reuters
04:45PM  Apple, Delta, Intel and 3M sink while Celgene soars Associated Press
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for hematological cancers. The company has agreement with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaboration with Skyhawk Therapeutics, Inc. and Dragonfly Therapeutics, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARIO ERNESTDirectorDec 19Option Exercise59.068,600507,87363,013Dec 20 04:48 PM
Biller JonathanEVP AND GENERAL COUNSELDec 16Option Exercise0.001,90004,046Dec 18 06:45 PM
VESSEY RUPERTSEE REMARKSDec 16Option Exercise0.005,35009,887Dec 18 06:43 PM
Curran TerrieSEE REMARKSDec 16Option Exercise0.002,50009,151Dec 18 06:28 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYDec 16Option Exercise0.003,000013,038Dec 18 06:26 PM
Alles Mark JCEO, CHAIRMAN OF BOARDDec 16Option Exercise0.008,9290196,245Dec 18 06:25 PM
MARIO ERNESTDirectorNov 26Option Exercise59.0610,000590,55054,413Nov 28 04:05 PM
MARIO ERNESTDirectorAug 09Sale92.3212,0001,107,88844,413Aug 13 04:05 PM
BARKER RICHARD WDirectorJun 17Option Exercise0.001,000012,846Jun 18 04:00 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00334037,436Jun 18 04:00 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00334056,413Jun 18 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037501,250Jun 15 04:57 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375056,079Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037501,050Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441037,102Jun 15 04:13 PM
Friedman Michael ADirectorJun 15Option Exercise0.002,41300Jun 15 04:12 PM
Haller Julia ADirectorJun 14Option Exercise0.003000875Jun 15 04:57 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300055,704Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.003000675Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300034,661Jun 15 04:13 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 15 04:12 PM
COX CARRIE SMITHDirectorJun 12Option Exercise0.006,200030,080Jun 14 04:35 PM
CASEY MICHAEL DDirectorJun 07Option Exercise30.0127,750832,77827,750Jun 11 04:06 PM
CASEY MICHAEL DDirectorJun 07Sale78.7713,0001,024,0100Jun 11 04:06 PM
LOUGHLIN JAMES JDirectorJun 04Option Exercise30.0127,750832,77852,111Jun 05 04:15 PM
LOUGHLIN JAMES JDirectorJun 04Sale78.9617,7501,401,54034,361Jun 05 04:15 PM
Masoudi GeraldSEE REMARKSJun 01Option Exercise0.0015,000020,235Jun 05 04:09 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 09Buy82.601,20899,784187,316May 17 04:08 PM
Curran TerrieMay 04Option Exercise0.002,50007,507May 08 04:56 PM
VESSEY RUPERTMay 04Option Exercise0.0078103,731May 08 04:36 PM
KELLOGG PETER NMay 04Option Exercise0.003,500050,831May 08 04:34 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 04Option Exercise0.003,5000187,627May 08 04:30 PM
LOUGHLIN JAMES JDirectorMar 12Option Exercise27.189,250251,41533,611Mar 13 04:22 PM
LOUGHLIN JAMES JDirectorMar 12Sale92.019,250851,09324,361Mar 13 04:22 PM
MARIO ERNESTDirectorFeb 23Sale94.4913,3701,263,29855,404Feb 26 04:11 PM
KAPLAN GILLADirectorFeb 20Sale94.839,250877,17876,301Feb 20 05:02 PM
Smith Scott AndrewSee RemarksFeb 17Option Exercise0.007,283051,748Feb 20 05:03 PM
KELLOGG PETER NSee RemarksFeb 17Option Exercise0.007,283049,660Feb 20 05:03 PM
Alles Mark JSee RemarksFeb 17Option Exercise0.007,2830186,187Feb 20 05:00 PM
KAPLAN GILLADirectorFeb 15Option Exercise27.189,250251,41594,801Feb 20 05:02 PM
KAPLAN GILLADirectorFeb 15Sale95.999,250887,89885,551Feb 20 05:02 PM
Alles Mark JSee RemarksFeb 08Buy91.903,260299,594178,904Feb 08 04:47 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62305,623Feb 05 04:39 PM